Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Last revisionBoth sides next revision
home:diseases:hypertension [01.04.2019] – [Recent research] sallieqhome:diseases:hypertension [03.30.2020] – [Hypertension (high blood pressure)] sallieq
Line 6: Line 6:
  
  
 +<relatedarticle> [[home:protocol:olmesartan#other beneficial effects|Science behind Olmesartan, section on cardiovascular_disease]] </article>
 ===== Introduction ===== ===== Introduction =====
  
Line 19: Line 20:
 Follow your doctor's advice regarding monitoring your blood pressure to determine if your current blood pressure medication/s are effective. Your blood pressure will come down as your Th1 inflammation resolves and you will need less blood pressure medication and then may no longer need additional B/P medication. Your doctor will advise you on how and when to adjust your blood pressure medication/s. Follow your doctor's advice regarding monitoring your blood pressure to determine if your current blood pressure medication/s are effective. Your blood pressure will come down as your Th1 inflammation resolves and you will need less blood pressure medication and then may no longer need additional B/P medication. Your doctor will advise you on how and when to adjust your blood pressure medication/s.
  
-If your B/P is too high, we suggest adding a beta blocker, an ACE inhibitor or a calcium channel blocker (in that order of perference) to your ARB (Benicar).+If your B/P is too high, it is possible to add a beta blocker, an ACE inhibitor or a calcium channel blocker (in that order of perference) to your ARB (Benicar).
  
 ==== If your BP rises on the MP ==== ==== If your BP rises on the MP ====
Line 116: Line 117:
 Olmesartan ameliorated arterial stiffness in patients with hypertension, which may be involved in the reduction of serum A-FABP.   (({{pubmed>long:21063874}})) Olmesartan ameliorated arterial stiffness in patients with hypertension, which may be involved in the reduction of serum A-FABP.   (({{pubmed>long:21063874}}))
  
-Given the involvement of oxidative stress and its signaling in atherogenesis, and the available evidence of olmesartan's vasoprotective, anti-inflammatory and antiatherosclerotic effects derived from clinical trials in humans, the results of our study provide a mechanistic rationale for the omelsartan's antioxidant and anti-inflammatory potential translation, in the long term, toward the antiatherosclerotic and antiremodeling effects reported on the clinical ground.  (({{pubmed>long:21504378}}))+Given the involvement of oxidative stress and its signaling in atherogenesis, and the available evidence of olmesartan's vasoprotective, anti-inflammatory and antiatherosclerotic effects derived from clinical trials in humans, the results of our study provide a mechanistic rationale for the olmesartan's antioxidant and anti-inflammatory potential translation, in the long term, toward the antiatherosclerotic and antiremodeling effects reported on the clinical ground.  (({{pubmed>long:21504378}}))
  
 {{tag>disease symptoms }} {{tag>disease symptoms }}
home/diseases/hypertension.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.